Anahita Mojiri1, Brandon K Walther1,2, Chongming Jiang3, Gianfranco Matrone4, Rhonda Holgate1, Qiu Xu1, Elisa Morales1, Guangyu Wang1,5, Jianhua Gu1, Rongfu Wang6, John P Cooke1. 1. Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, Houston Methodist Research Institute, 6670 Bertner Ave., R10-South, Houston, TX 77030, USA. 2. Department of Biomedical Engineering, Texas A&M University, 101 Bizzell St., College Station, TX 77840, USA. 3. Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. 4. British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK. 5. Center for Bioinformatics and Computational Biology, Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX 77030, USA. 6. Department of Medicine, and Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.
Abstract
AIMS: Hutchinson-Gilford progeria syndrome (HGPS) is an accelerated ageing syndrome associated with premature vascular disease and death due to heart attack and stroke. In HGPS a mutation in lamin A (progerin) alters nuclear morphology and gene expression. Current therapy increases the lifespan of these children only modestly. Thus, greater understanding of the underlying mechanisms of HGPS is required to improve therapy. Endothelial cells (ECs) differentiated from induced pluripotent stem cells (iPSCs) derived from these patients exhibit hallmarks of senescence including replication arrest, increased expression of inflammatory markers, DNA damage, and telomere erosion. We hypothesized that correction of shortened telomeres may reverse these measures of vascular ageing. METHODS AND RESULTS: We generated ECs from iPSCs belonging to children with HGPS and their unaffected parents. Telomerase mRNA (hTERT) was used to treat HGPS ECs. Endothelial morphology and functions were assessed, as well as proteomic and transcriptional profiles with attention to inflammatory markers, DNA damage, and EC identity genes. In a mouse model of HGPS, we assessed the effects of lentiviral transfection of mTERT on measures of senescence, focusing on the EC phenotype in various organs. hTERT treatment of human HGPS ECs improved replicative capacity; restored endothelial functions such as nitric oxide generation, acetylated low-density lipoprotein uptake and angiogenesis; and reduced the elaboration of inflammatory cytokines. In addition, hTERT treatment improved cellular and nuclear morphology, in association with a normalization of the transcriptional profile, effects that may be mediated in part by a reduction in progerin expression and an increase in sirtuin 1 (SIRT1). Progeria mice treated with mTERT lentivirus manifested similar improvements, with a reduction in inflammatory and DNA damage markers and increased SIRT1 in their vasculature and other organs. Furthermore, mTERT therapy increased the lifespan of HGPS mice. CONCLUSION: Vascular rejuvenation using telomerase mRNA is a promising approach for progeria and other age-related diseases. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Hutchinson-Gilford progeria syndrome (HGPS) is an accelerated ageing syndrome associated with premature vascular disease and death due to heart attack and stroke. In HGPS a mutation in lamin A (progerin) alters nuclear morphology and gene expression. Current therapy increases the lifespan of these children only modestly. Thus, greater understanding of the underlying mechanisms of HGPS is required to improve therapy. Endothelial cells (ECs) differentiated from induced pluripotent stem cells (iPSCs) derived from these patients exhibit hallmarks of senescence including replication arrest, increased expression of inflammatory markers, DNA damage, and telomere erosion. We hypothesized that correction of shortened telomeres may reverse these measures of vascular ageing. METHODS AND RESULTS: We generated ECs from iPSCs belonging to children with HGPS and their unaffected parents. Telomerase mRNA (hTERT) was used to treat HGPS ECs. Endothelial morphology and functions were assessed, as well as proteomic and transcriptional profiles with attention to inflammatory markers, DNA damage, and EC identity genes. In a mouse model of HGPS, we assessed the effects of lentiviral transfection of mTERT on measures of senescence, focusing on the EC phenotype in various organs. hTERT treatment of human HGPS ECs improved replicative capacity; restored endothelial functions such as nitric oxide generation, acetylated low-density lipoprotein uptake and angiogenesis; and reduced the elaboration of inflammatory cytokines. In addition, hTERT treatment improved cellular and nuclear morphology, in association with a normalization of the transcriptional profile, effects that may be mediated in part by a reduction in progerin expression and an increase in sirtuin 1 (SIRT1). Progeria mice treated with mTERT lentivirus manifested similar improvements, with a reduction in inflammatory and DNA damage markers and increased SIRT1 in their vasculature and other organs. Furthermore, mTERT therapy increased the lifespan of HGPS mice. CONCLUSION: Vascular rejuvenation using telomerase mRNA is a promising approach for progeria and other age-related diseases. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Pekka Taimen; Katrin Pfleghaar; Takeshi Shimi; Dorothee Möller; Kfir Ben-Harush; Michael R Erdos; Stephen A Adam; Harald Herrmann; Ohad Medalia; Francis S Collins; Anne E Goldman; Robert D Goldman Journal: Proc Natl Acad Sci U S A Date: 2009-11-19 Impact factor: 11.205
Authors: Swami R Narala; Richard C Allsopp; Trystan B Wells; Guanglei Zhang; Prerna Prasad; Matthew J Coussens; Derrick J Rossi; Irving L Weissman; Homayoun Vaziri Journal: Mol Biol Cell Date: 2008-01-09 Impact factor: 4.138
Authors: Jérôme D Robin; Andrew T Ludlow; Kimberly Batten; Frédérique Magdinier; Guido Stadler; Kathyrin R Wagner; Jerry W Shay; Woodring E Wright Journal: Genes Dev Date: 2014-11-15 Impact factor: 11.361
Authors: Selma Osmanagic-Myers; Attila Kiss; Christina Manakanatas; Ouafa Hamza; Franziska Sedlmayer; Petra L Szabo; Irmgard Fischer; Petra Fichtinger; Bruno K Podesser; Maria Eriksson; Roland Foisner Journal: J Clin Invest Date: 2018-12-18 Impact factor: 14.808